Prothena Corporation plc (PRTA) Financial Ratios
16 years of historical data (2010–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: 25.00
30Y Low25.0·High25.0
P/FCF
N/A
—
5yr avg: 26.01
30Y Low26.0·High26.0
P/B Ratio
↓
2.15
↓-35% vs avg
5yr avg: 3.31
30Y Low0.8·High5.7
ROE
↓
-63.6%
↑-182% vs avg
5yr avg: -22.5%
30Y Low-69%·High21%
Debt/EBITDA
N/A
—
5yr avg: 0.17
30Y Low0.2·High0.2
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
PRTA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Prothena Corporation plc currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $602M | $514M | $745M | $1.9B | $2.9B | $2.4B | $479M | $631M | $407M | $1.4B | $1.7B |
| Enterprise Value | $308M | $220M | $284M | $1.3B | $2.2B | $1.8B | $202M | $279M | $31M | $1.0B | $1.4B |
| P/E Ratio → | -2.47 | — | — | — | — | 35.80 | — | — | — | — | — |
| P/S Ratio | 62.15 | 53.08 | 5.51 | 21.17 | 52.94 | 11.94 | 561.99 | 775.59 | 426.66 | 51.30 | 1601.64 |
| P/B Ratio | 2.15 | 1.83 | 1.53 | 3.44 | 4.59 | 5.14 | 2.61 | 2.31 | 1.26 | 3.47 | 4.62 |
| P/FCF | — | — | — | — | — | 26.01 | — | — | — | — | — |
| P/OCF | — | — | — | — | — | 25.85 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
PRTA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 22.76 | 2.10 | 14.52 | 39.89 | 9.11 | 236.62 | 342.20 | 32.82 | 38.02 | 1283.53 |
| EV / EBITDA | — | — | — | — | — | 25.00 | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | 25.39 | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | 19.86 | — | — | — | — | — |
PRTA Profitability
Margins and return-on-capital ratios measuring operating efficiency
Prothena Corporation plc earns an operating margin of -1905.8%. Operating margins have compressed from -209.1% to -1905.8% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -63.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.8% | 61.8% | 100.0% | 100.0% | 100.0% | 100.0% | -8678.9% | -6145.2% | -10495.1% | -388.9% | -11230.2% |
| Operating Margin | -1905.8% | -1905.8% | -114.4% | -209.1% | -244.1% | 35.9% | -13216.2% | -10527.9% | -16634.0% | -564.2% | -15121.8% |
| Net Profit Margin | -2520.6% | -2520.6% | -90.5% | -160.9% | -217.0% | 33.4% | -13029.8% | -9542.6% | -16297.9% | -556.8% | -15176.1% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -63.6% | -63.6% | -23.3% | -24.8% | -21.5% | 20.6% | -48.6% | -26.1% | -42.6% | -39.7% | -44.1% |
| ROA | -55.9% | -55.9% | -19.7% | -20.2% | -17.1% | 14.2% | -29.5% | -16.9% | -31.3% | -32.0% | -37.9% |
| ROIC | -2099.8% | -2099.8% | -439.4% | — | — | — | — | — | — | -325.2% | -1203.6% |
| ROCE | -47.0% | -47.0% | -27.2% | -28.4% | -20.5% | 16.3% | -31.8% | -19.4% | -33.7% | -35.4% | -40.8% |
PRTA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $308M exceeds total debt of $14M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.05 | 0.02 | 0.02 | 0.01 | 0.03 | 0.10 | 0.08 | 0.16 | 0.13 | 0.14 |
| Debt / EBITDA | — | — | — | — | — | 0.17 | — | — | — | — | — |
| Net Debt / Equity | — | -1.05 | -0.95 | -1.08 | -1.13 | -1.22 | -1.51 | -1.29 | -1.16 | -0.90 | -0.92 |
| Net Debt / EBITDA | — | — | — | — | — | -7.75 | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | -6.16 | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | -41.23 | -41.73 | -184.20 |
Net cash position: cash ($308M) exceeds total debt ($14M)
PRTA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Prothena Corporation plc's current ratio of 7.72x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 11.24x to 7.72x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.72 | 7.72 | 10.01 | 11.24 | 14.34 | 17.48 | 11.58 | 21.36 | 28.90 | 11.41 | 9.53 |
| Quick Ratio | 7.72 | 7.72 | 10.01 | 11.24 | 14.34 | 17.48 | 11.58 | 21.36 | 28.90 | 11.41 | 9.53 |
| Cash Ratio | 7.53 | 7.53 | 9.72 | 10.88 | 14.17 | 17.31 | 11.43 | 21.21 | 28.65 | 11.17 | 9.42 |
| Asset Turnover | — | 0.03 | 0.25 | 0.13 | 0.07 | 0.33 | 0.00 | 0.00 | 0.00 | 0.06 | 0.00 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | 20.61 | 0.42 | 0.02 | 6.42 | 30.49 | 0.76 | 3.18 | 61.58 |
PRTA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Prothena Corporation plc does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 2.8% | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | 3.8% | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $54M | $54M | $53M | $47M | $48M | $40M | $40M | $40M | $38M | $34M |
Peer Comparison
Compare PRTA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 PRTAYou | $602M | -2.5 | — | — | 61.8% | -1905.8% | -63.6% | -2099.8% | — |
 FOLD | $4B | -80.5 | 140.6 | — | 90.0% | 4.7% | -31.7% | 4.8% | 13.3 |
 RARE | $3B | -4.4 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 IONS | $13B | -32.3 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 ALNY | $40B | 130.0 | 71.9 | 86.9 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 RCUS | $3B | -7.9 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 BIIB | $28B | 21.6 | 11.4 | 13.7 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
 REGN | $75B | 17.4 | 18.1 | 18.4 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 ARVN | $656M | -8.0 | — | — | 98.0% | -43.8% | -16.2% | -22.4% | — |
 NTLA | $2B | -3.6 | — | — | — | — | -53.5% | — | — |
 BEAM | $3B | -39.9 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 16 years · Updated daily
See PRTA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PRTA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PRTA vs FOLD
Side-by-side business, growth, and profitability comparison vs Amicus Therapeutics, Inc..
Start ComparisonPRTA — Frequently Asked Questions
Quick answers to the most common questions about buying PRTA stock.
What is Prothena Corporation plc's P/E ratio?
Prothena Corporation plc's current P/E ratio is -2.5x. The historical average is 35.8x.
What is Prothena Corporation plc's ROE?
Prothena Corporation plc's return on equity (ROE) is -63.6%. The historical average is -31.3%.
Is PRTA stock overvalued?
Based on historical data, Prothena Corporation plc is trading at a P/E of -2.5x. Compare with industry peers and growth rates for a complete picture.
What are Prothena Corporation plc's profit margins?
Prothena Corporation plc has 61.8% gross margin and -1905.8% operating margin.